Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide
· Lundbeck and Otsuka, two companies with a rich CNS heritage, form a global alliance to focus on delivering up to five innovative psychiatric and neuroscience products in a multi-billion DKK deal · Lundbeck and Otsuka will work closely together to develop and commercialise new medicines to patients in an area of substantial unmet medical needs · Lundbeck is granted co-development and co-commercialisation rights to aripiprazole depot formulation in North and Latin America as well as Europe, Australia and some other countries · Lundbeck is granted co-development and co-